Intellia Therapeutics, Inc. Q1 FY26 Results

Summary

Intellia Therapeutics announced a public offering of its common stock, estimating net proceeds of approximately $194.6 million. These funds are intended to advance clinical development and for other corporate purposes. Preliminary unaudited cash, cash equivalents, and marketable securities as of March 31, 2026, were approximately $517.2 million. The company also raised $33.6 million from an “at the market” equity offering program during the quarter ended March 31, 2026.

Key Highlights

1. 1

   Intellia Therapeutics entered into an underwriting agreement for a public offering on April 28, 2026.

2. 2

   The company offered 16,744,187 shares of common stock at $10.75 per share.

3. 3

   The underwriters exercised their option to purchase an additional 2,511,628 shares.

4. 4

   The company estimates net proceeds from the offering to be approximately $194.6 million.

5. 5

   Intellia plans to use the net proceeds to advance clinical development, research, and for general corporate purposes.

6. 6

   Preliminary unaudited cash, cash equivalents, and marketable securities as of March 31, 2026, were approximately $517.2 million.

7. 7

   The company raised approximately $33.6 million in net proceeds from the sale of shares under an “at the market” equity offering program during the quarter ended March 31, 2026.